luspatercept,epoetin alfa
bms
['mds', 'lusp']
taking a massively costly drug to prevent a few transfusions is a bad study
luspatercept. hrqol should be the endpoint and power should exclude os detriment. conference is a sea of studies that help companies not people #mds
#asco23
Professor @ucsf, Physician-Scientist, Writer; More at @vkprasadlab @plenary_session, YouTube, #vpzd podcast & @Sensible__Med; Views are mine